Edition:
India

Allergan plc (AGN.N)

AGN.N on New York Stock Exchange

162.09USD
23 Feb 2018
Change (% chg)

$2.69 (+1.69%)
Prev Close
$159.40
Open
$161.53
Day's High
$162.50
Day's Low
$160.05
Volume
808,104
Avg. Vol
715,298
52-wk High
$256.78
52-wk Low
$156.00

Chart for

About

Allergan plc is a specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of brand name pharmaceutical products, medical aesthetics, biosimilar and over-the-counter pharmaceutical products. The Company operates through three segments: US Specialized Therapeutics, US... (more)

Overall

Beta: 1.17
Market Cap(Mil.): $69,117.80
Shares Outstanding(Mil.): 334.31
Dividend: 0.70
Yield (%): 1.35

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.60
EPS (TTM): -- -- --
ROI: -- 14.91 10.66
ROE: -- 16.41 14.30

BRIEF-FDA Acceptance Of Medicines360's Filing For Supplemental NDA For Liletta 52 Mg

* FDA ACCEPTANCE OF MEDICINES360'S FILING FOR SUPPLEMENTAL NEW DRUG APPLICATION FOR LILETTA® (LEVONORGESTREL-RELEASING INTRAUTERINE SYSTEM) 52 MG Source text for Eikon: Further company coverage:

22 Feb 2018

BRIEF-Molecular Partners' Partner Allergan Exercises Third Option For Darpin Product Candidate In Ophthalmology

* MOLECULAR PARTNERS' PARTNER ALLERGAN EXERCISES THIRD OPTION FOR DARPIN PRODUCT CANDIDATE IN OPHTHALMOLOGY Source text for Eikon: Further company coverage: (Gdynia Newsroom)

19 Feb 2018

BRIEF-Allergan Files For Potential Mixed Shelf Offering

* ALLERGAN PLC FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED - SEC FILING Source text: (http://bit.ly/2EvYOO0) Further company coverage:

17 Feb 2018

Shares of Apricus tank after FDA declines to OK erectile dysfunction cream

The U.S. Food and Drug Administration on Friday declined to approve Apricus Biosciences Inc's Vitaros, a cream to treat erectile dysfunction, for the second time in a decade, sending the company's shares down more than 70 percent before the opening bell.

16 Feb 2018

UPDATE 2-Shares of Apricus tank after FDA declines to OK erectile dysfunction cream

* Co set to lose 76 pct of market value (Adds background on drug, analyst comment, updates share price)

16 Feb 2018

BRIEF-Appaloosa Dissolves Share Stake In GM & Whirlpool, Ups Stake In Allergan

* APPALOOSA LP DISSOLVES SHARE STAKE IN GENERAL MOTORS CO - SEC FILING

15 Feb 2018

BRIEF-Allergan Declares Q1 2018 Cash Dividend Of $0.72 Per Share

* ALLERGAN DECLARES FIRST QUARTER 2018 CASH DIVIDEND OF $0.72 PER ORDINARY SHARE AND PROVIDES ANNUAL GENERAL MEETING OF SHAREHOLDERS UPDATES Source text for Eikon: Further company coverage:

09 Feb 2018

Allergan's profit beats; migraine drug succeeds in key study

Allergan Plc on Tuesday reported better-than-expected quarterly profit on robust demand for Botox, boosted its earnings forecast and announced positive data on one of the two migraine treatments it is developing.

06 Feb 2018

UPDATE 3-Allergan's profit beats; migraine drug succeeds in key study

Feb 6 Allergan Plc on Tuesday reported better-than-expected quarterly profit on robust demand for Botox, boosted its earnings forecast and announced positive data on one of the two migraine treatments it is developing.

06 Feb 2018

Allergan's profit beats; migraine drug succeeds in key study

Allergan Plc on Tuesday reported a better-than-expected quarterly profit on strong demand for Botox, and said its migraine treatment met the main goals in a late-stage study.

06 Feb 2018

Earnings vs. Estimates